RPRX logo

ROYALTY PHARMA PLC- CL A

RPRXNASDAQ
🏆 #400 by market capUS Equity
$58.32▼ $0.05 (−0.09%)
Live
🔔
Track RPRX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.1%
7d▼ 0.3%
14d▼ 0.2%
30d▼ 4.2%
ytd▲ 50.9%
1y▲ 65.5%
🏦Market Cap
$33.58B
Mid Cap
📈Revenue Growth (YoY)
+10.0%
Healthy
📊Gross Margin
—
💵FCF Margin
33.0%
Strong
⚖️P/S Ratio
13.2x
Elevated
Otter Score
60
Fair

Trading Snapshot

Day Range
$57.77 – $58.75
52-Week Range
$34.63 – $64.38
Volume
$3.86B
Avg Volume
$4.34B
Shares Outstanding
575.8M
Next Earnings
Nov 15, 2026

Fundamentals Snapshot

Annual Revenue
$2.38B
Last Q Revenue
$674M
P/E Ratio
41.2
P/S Ratio
13.2x
EPS (TTM)
$1.46
Dividend Yield
1.19%

Why Investors Own RPRX

  • ✓High-growth profile — revenue up +27.6% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 78% gross margin and 23% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

RPRX logo

ROYALTY PHARMA PLC- CL A

RPRX
Financial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$2.38B▲ +30.0% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
78.4%▲ +0.2% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$283M▲ +30.0% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$554M▲ +30.0% YoY
StockOtter · stockotter.space

About ROYALTY PHARMA PLC- CL A

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$61.22
▲ +5.0% Upside
High Target$71.90
Low Target$51.50
Based on 11 analysts

Latest News & Updates

🚀
CNBC·2h ago

ROYALTY PHARMA PLC- CL A tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift RPRX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

ROYALTY PHARMA PLC- CL A announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.